Skip to main content

United States News All stories

Every story in this section, newest first — page 312 of 373.

Grafa
Health

Mirum Pharmaceuticals clinches Bluejay acquisition to lead in rare liver disease

Mirum Pharmaceuticals (NASDAQ:MIRM) announced the successful closing of its acquisition of Bluejay Therapeutics, a move that significantly broadens its rare disease pipeline with a potential first-in-class therapy for chronic hepatitis delta virus (HDV).

Read more: Mirum Pharmaceuticals clinches Bluejay acquisition to lead in rare liver disease
Grafa
Health

United Therapeutics bioengineered liver passes initial human safety test

United Therapeutics (NASDAQ:UTHR) has cleared a primary safety hurdle in its ambitious effort to manufacture biological alternatives to human organs, reporting that its bioengineered external liver supported critically ill patients without serious adverse effects.

Read more: United Therapeutics bioengineered liver passes initial human safety test
Grafa
Oil and Gas

Baker Hughes tops estimates as gas technology pivot offsets oilfield softness

Baker Hughes (NASDAQ:BKR) reported fourth-quarter profits that comfortably cleared analyst hurdles, as the company’s strategic shift toward liquefied natural gas (LNG) and industrial energy technology bore fruit against a volatile backdrop for crude prices.

Read more: Baker Hughes tops estimates as gas technology pivot offsets oilfield softness
Grafa
Health

FDA grants priority review to Biogen and Eisai’s at-home Alzheimer’s injectable

Biogen (NASDAQ:BIIB) and Eisai have cleared a significant regulatory hurdle as the U.S. Food and Drug Administration (FDA) accepted their supplemental Biologics License Application for a subcutaneous version of the Alzheimer’s treatment Leqembi.

Read more: FDA grants priority review to Biogen and Eisai’s at-home Alzheimer’s injectable